Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?

Wiener Medizinische Wochenschrift

Volumn 160, Issue 17-18, 2010, Pages 452-457

  Wagner, Doris ^a   Fahrleitner Pammer, Astrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Clinical studies; Hepatic osteodystrophy; Metabolic bone disease; OPG RANKL RANK; Osteoporosis

Indexed keywords

ALENDRONIC ACID; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID;

BODY MASS; BONE DENSITY; BONE METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DRUG WITHDRAWAL; FRAGILITY FRACTURE; GROUPS BY AGE; HEPATIC OSTEODYSTROPHY; HUMAN; KIDNEY FAILURE; LIVER DISEASE; OSTEOCLAST; OSTEODYSTROPHY; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; TREATMENT WITHDRAWAL;

AGED; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; CELL DIVISION; CELL SURVIVAL; FRACTURES, SPONTANEOUS; HUMANS; LIVER; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RANK LIGAND;

EID: 78149407953     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0818-x     Document Type: Review

References (70)

1. WS Simonet DL Lacey CR Dunstan, et al. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 2 309 319 1:CAS:528:DyaK2sXislCgtLc%3D 10.1016/S0092-8674(00)80209-3 9108485
2. H Yasuda N Shima N Nakagawa, et al. 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 3 1329 1337 10.1210/en.139.3.1329 9492069 (Pubitemid 28510154)
3. H Yasuda N Shima N Nakagawa, et al. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 7 3597 3602 1:CAS:528:DyaK1cXitlKjsLY%3D 10.1073/pnas.95.7.3597 9520411 (Pubitemid 28173173)
4. YY Kong U Feige I Sarosi, et al. 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 6759 304 309 1:CAS:528:DyaK1MXnvFShsLg%3D 10.1038/46303 10580503
5. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 165 176 1:CAS:528:DyaK1cXivVyhtrg%3D 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
6. DM Anderson E Maraskovsky WL Billingsley, et al. 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 6656 175 179 1:CAS:528:DyaK2sXnsVOgurY%3D 10.1038/36593 9367155 (Pubitemid 27507987)
7. H Hsu DL Lacey CR Dunstan, et al. 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc Natl Acad Sci USA 96 7 3540 3545 1:CAS:528:DyaK1MXjslCitL8%3D 10.1073/pnas.96.7.3540 10097072 (Pubitemid 29168945)
8. K Fuller B Wong S Fox, et al. 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts J Exp Med 188 5 997 1001 1:CAS:528:DyaK1cXmtVagtb8%3D 10.1084/jem.188.5.997 9730902 (Pubitemid 28433427)
9. YY Kong WJ Boyle JM Penninger 2000 Osteoprotegerin ligand: a regulator of immune responses and bone physiology Immunol Today 21 10 495 502 1:CAS:528:DC%2BD3cXmvFyltrY%3D 10.1016/S0167-5699(00)01718-7 11071528
10. LC Hofbauer 1999 Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism Eur J Endocrinol 141 3 195 210 1:CAS:528:DyaK1MXmsFWnsb0%3D 10.1530/eje.0.1410195 10474114 (Pubitemid 29465922)
11. LC Hofbauer S Khosla CR Dunstan, et al. 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J Bone Miner Res 15 1 2 12 1:CAS:528:DC%2BD3cXmsVygsQ%3D%3D 10.1359/jbmr.2000.15. 1.2 10646108
12. N Bucay I Sarosi CR Dunstan, et al. 1998 osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 9 1260 1268 1:CAS:528:DyaK1cXjtVejsrs%3D 10.1101/gad.12.9.1260 9573043
13. A Mizuno N Amizuka K Irie, et al. 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin Biochem Biophys Res Commun 247 3 610 615 1:CAS:528:DyaK1cXkt12htr8%3D 10.1006/bbrc.1998.8697 9647741 (Pubitemid 28418439)
14. PJ Bekker D Holloway A Nakanishi, et al. 2001 The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2 348 360 1:CAS:528:DC%2BD3MXptlOquw%3D%3D 10.1359/jbmr.2001.16.2.348 11204435
15. LC Hofbauer M Schoppet 2001 Serum measurement of osteoprotegerin - clinical relevance and potential applications Eur J Endocrinol 145 6 681 683 1:CAS:528:DC%2BD3MXpt1Ght74%3D 10.1530/eje.0.1450681 11720890
16. A Rogers R Eastell 2005 Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment J Clin Endocrinol Metab 90 11 6323 6331 1:CAS:528: DC%2BD2MXht1altLzO 10.1210/jc.2005-0794 16105967 (Pubitemid 41606564)
17. O Alexopoulou J Jamart JP Devogelaer, et al. 2006 Bone density and markers of bone remodeling in type 1 male diabetic patients Diabetes Metab 32 5 Pt 1 453 458 1:CAS:528:DC%2BD2sXhvVKhtw%3D%3D 10.1016/S1262-3636(07)70303-8 17110900 (Pubitemid 44836587)
18. H Uemura T Yasui Y Miyatani, et al. 2008 Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in post-menopausal women J Endocrinol Invest 31 2 163 168 1:CAS:528: DC%2BD1cXmt1emsbs%3D 18362509
19. HY Zhao JM Liu G Ning, et al. 2008 Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women Osteoporos Int 19 2 221 226 1:CAS:528:DC%2BD1cXitVSqtA%3D%3D 10.1007/s00198-007-0440-y 17703270
20. S Kudlacek B Schneider W Woloszczuk, et al. 2003 Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 6 681 686 1:CAS:528:DC%2BD3sXks1WksLc%3D 10.1016/S8756-3282(03)00090-5 12810175 (Pubitemid 37303940)
21. S Kudlacek R Willvonseder P Stohlawetz, et al. 2000 Immunology and aging Aging Male 3 3 137 142 1:STN:280:DC%2BD28zksFOluw%3D%3D 10.1080/ 13685530008500340 16760149
22. I Nabipour B Larijani K Vahdat, et al. 2009 Relationships among serum receptor of nuclear factor-kappa B ligand, osteoprotegerin, high- sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory Menopause 16 5 950 955 10.1097/gme.0b013e3181a181b8 19387415
23. A Fahrleitner-Pammer H Dobnig C Piswanger-Soelkner, et al. 2003 Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status Wien Klin Wochenschr 115 9 291 297 1:CAS:528:DC%2BD2cXltVen 10.1007/BF03040334 12793029
24. D Grigorie E Neacsu M Marinescu O Popa 2003 Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis Rom J Intern Med 41 4 409 415 1:CAS:528:DC%2BD2cXntVels70%3D 15526523
25. P Mezquita-Raya M de la Higuera DF Garcia G Alonso, et al. 2005 The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women Osteoporos Int 16 11 1368 1374 10.1007/s00198-005-1844-1 15711777 (Pubitemid 41532089)
26. ES Oh EJ Rhee KW Oh, et al. 2005 Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women Metabolism 54 1 49 54 1:CAS:528:DC%2BD2cXhtVansbrN 10.1016/j.metabol.2004.08.005 15562379 (Pubitemid 39572456)
27. KW Oh EJ Rhee WY Lee, et al. 2005 Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males Clin Endocrinol (Oxf) 62 1 92 98 1:CAS:528:DC%2BD2MXhvFKqsbY%3D 10.1111/j.1365-2265.2004.02179.x (Pubitemid 40175289)
28. B Abrahamsen JV Hjelmborg P Kostenuik, et al. 2005 Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins Bone 36 4 727 735 1:CAS:528:DC%2BD2MXjs1Kru78%3D 10.1016/j.bone.2004.12.015 15781001 (Pubitemid 40602267)
29. NG Angelopoulos A Goula E Katounda, et al. 2007 Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major J Bone Miner Metab 25 1 60 67 1:CAS:528: DC%2BD28XhtlGitbbL 10.1007/s00774-006-0728-6 17187195 (Pubitemid 46012998)
30. P Oelzner S Franke G Lehmann, et al. 2007 Soluble receptor activator of NFkappaB-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover Clin Rheumatol 26 12 2127 2135 1:STN:280:DC%2BD2snmsFagsw%3D%3D 10.1007/s10067-007-0639-5 17541498 (Pubitemid 350120353)
31. M Gugatschka A Hoeller A Fahrleitner-Pammer, et al. 2007 Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men J Endocrinol Invest 30 1 46 51 1:CAS:528:DC%2BD2sXktFOjtrw%3D 17318022
32. P Pennisi SS Signorelli S Riccobene, et al. 2004 Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels Osteoporos Int 15 5 389 395 1:STN:280:DC%2BD2c3gsFKiuw%3D%3D 10.1007/s00198-003-1550-9 14661073 (Pubitemid 38639334)
33. P Szulc LC Hofbauer AE Heufelder, et al. 2001 Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status J Clin Endocrinol Metab 86 7 3162 3165 1:CAS:528:DC%2BD3MXlt1Gjt78%3D 10.1210/jc.86.7.3162 11443182 (Pubitemid 32673481)
34. A Stern GA Laughlin J Bergstrom E Barrett-Connor 2007 The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study Eur J Endocrinol 156 5 555 562 1:CAS:528:DC%2BD2sXls1ynsbw%3D 10.1530/EJE-06-0753 17468191 (Pubitemid 46796522)
35. G Coen P Ballanti MS Fischer, et al. 2003 Serum leptin in dialysis renal osteodystrophy Am J Kidney Dis 42 5 1036 1042 1:CAS:528:DC%2BD3sXpt1Ogur4%3D 10.1016/j.ajkd.2003.07.005 14582047
36. M Holecki B Zahorska-Markiewicz J Janowska, et al. 2007 Osteoprotegerin - does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? Endokrynol Pol 58 1 7 10 17354199
37. R Ohwada M Hotta K Sato, et al. 2007 The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa Endocr J 54 6 953 959 1:CAS:528:DC%2BD1cXjtFans7k%3D 10.1507/endocrj.K07-034 17998762 (Pubitemid 351346779)
38. F Szalay D Hegedus PL Lakatos, et al. 2003 High serum osteoprotegerin and low RANKL in primary biliary cirrhosis J Hepatol 38 4 395 400 1:CAS:528:DC%2BD3sXit1yqurc%3D 10.1016/S0168-8278(02)00435-X 12663228 (Pubitemid 36399239)
39. H Dobnig LC Hofbauer V Viereck, et al. 2006 Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients Osteoporos Int 17 5 693 703 1:CAS:528:DC%2BD28XjsVertrw%3D 10.1007/s00198-005-0035-4 16435076
40. A Fahrleitner G Prenner D Kniepeiss, et al. 2002 Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status Wien Klin Wochenschr 114 15-16 717 724 1:CAS:528:DC%2BD38XotFOktL0%3D 12602117
41. E Fabrega A Orive C Garcia-Suarez, et al. 2005 Osteoprotegerin and RANKL in alcoholic liver cirrhosis Liver Int 25 2 305 310 1:CAS:528: DC%2BD2MXjs1OgsLk%3D 10.1111/j.1478-3231.2005.01073.x 15780054
42. CE Fiore P Pennisi G Ferro, et al. 2006 Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet Horm Metab Res 38 6 417 422 1:CAS:528:DC%2BD28XmvFyhtbg%3D 10.1055/s-2006-944548 16823725 (Pubitemid 44055792)
43. M Herrmann M Kraenzlin G Pape, et al. 2005 Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women Clin Chem Lab Med 43 10 1118 1123 1:CAS:528: DC%2BD2MXhtFyjsr%2FO 10.1515/CCLM.2005.195 16197308 (Pubitemid 41581971)
44. A Monegal M Navasa P Peris, et al. 2007 Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease Liver Int 27 4 492 497 1:CAS:528:DC%2BD2sXlvFyksb8%3D 10.1111/j.1478-3231.2007.01448.x 17403189 (Pubitemid 46534571)
45. Y Chiba T Onouchi T Ikeda, et al. 2009 Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women Gerontology 55 3 275 280 1:CAS:528: DC%2BD1MXmtFektLk%3D 10.1159/000196280 19158438
46. Y Dai L Shen 2007 Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women Chin Med J (Engl) 120 22 2017 2021 1:CAS:528:DC%2BD1cXjtlWr
47. A Fahrleitner G Prenner G Leb, et al. 2003 Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation Bone 32 1 96 106 1:CAS:528: DC%2BD3sXhtVantLc%3D 10.1016/S8756-3282(02)00926-2 12584041 (Pubitemid 36173817)
48. CN Bernstein 2006 Inflammatory bowel diseases as secondary causes of osteoporosis Curr Osteoporos Rep 4 3 116 123 10.1007/s11914-996-0031-4 16908001 (Pubitemid 44623934)
49. AR Moschen A Kaser S Stadlmann, et al. 2005 The RANKL/OPG system and bone mineral density in patients with chronic liver disease J Hepatol 43 6 973 983 10.1016/j.jhep.2005.05.034 16143421 (Pubitemid 41627982)
50. S Trofimov I Pantsulaia E Kobyliansky G Livshits 2004 Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population Eur J Endocrinol 150 3 305 311 1:CAS:528:DC%2BD2cXivFCktrk%3D 10.1530/eje.0.1500305 15012615 (Pubitemid 38443780)
51. A Fahrleitner-Pammer H Dobnig HP Dimai, et al. 2009 The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure Clin Nephrol 71 6 652 659 1:CAS:528:DC%2BD1MXovFSkt7Y%3D 19473634
52. G Schett S Kiechl K Redlich, et al. 2004 Soluble RANKL and risk of nontraumatic fracture JAMA 291 9 1108 1113 1:CAS:528:DC%2BD2cXhvFenurc%3D 10.1001/jama.291.9.1108 14996780 (Pubitemid 38541688)
53. EK Li LS Tam JF Griffith, et al. 2009 High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus J Rheumatol 36 8 1646 1652 10.3899/jrheum.081337 19605677
54. EM Messalli G Mainini C Scaffa, et al. 2007 Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women Maturitas 56 1 38 44 1:CAS:528:DC%2BD28XhtlaltrnI 10.1016/j.maturitas.2006.05.007 16787719 (Pubitemid 44894788)
55. D Fernandez-Garcia M Munoz-Torres P Mezquita-Raya, et al. 2008 Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis J Endocrinol Invest 31 5 416 421 1:CAS:528:DC%2BD1cXpslGrurY%3D 18560259
56. U Dundar V Kavuncu IH Ciftci, et al. 2009 The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study J Bone Miner Metab 27 4 464 470 1:CAS:528:DC%2BD1MXnvValtrs%3D 10.1007/s00774-009-0055-9 19301089
57. EC Buxton W Yao NE Lane 2004 Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34) J Clin Endocrinol Metab 89 7 3332 3336 1:CAS:528: DC%2BD2cXlslegsb4%3D 10.1210/jc.2003-032066 15240611 (Pubitemid 38951900)
58. AD Anastasilakis DG Goulis SA Polyzos, et al. 2008 Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide Eur J Endocrinol 158 3 411 415 1:CAS:528:DC%2BD1cXjsFylurg%3D 10.1530/EJE-07-0528 18299476 (Pubitemid 351405007)
59. AD Anastasilakis DG Goulis SA Polyzos, et al. 2008 Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial Horm Metab Res 40 4 281 285 1:CAS:528:DC%2BD1cXmt1Wls7k%3D 10.1055/s-2008-1046787 18275008 (Pubitemid 351533112)
60. R Reyes-Garcia M Munoz-Torres DF Garcia, et al. 2010 Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis Menopause 17 1 140 144 10.1097/gme.0b013e3181ac0cc1 19574937
61. P Miheller G Muzes K Racz, et al. 2007 Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy Inflamm Bowel Dis 13 11 1379 1384 10.1002/ibd.20234 17663430 (Pubitemid 350206849)
62. M Vis EA Havaardsholm G Haugeberg, et al. 2006 Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis Ann Rheum Dis 65 11 1495 1499 1:CAS:528:DC%2BD28Xht1OjtL3E 10.1136/ard.2005.044198 16606653 (Pubitemid 44629129)
63. R Cibulka J Racek R Pikner, et al. 2007 Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients Calcif Tissue Int 81 2 99 106 1:CAS:528: DC%2BD2sXosFOgs74%3D 10.1007/s00223-007-9041-1 17622482 (Pubitemid 47228730)
64. G Coen P Ballanti A Balducci, et al. 2002 Serum osteoprotegerin and renal osteodystrophy Nephrol Dial Transplant 17 2 233 238 1:CAS:528: DC%2BD38XitVSnsrw%3D 10.1093/ndt/17.2.233 11812872
65. M Fukagawa JJ Kazama K Kurokawa 2002 Renal osteodystrophy and secondary hyperparathyroidism Nephrol Dial Transplant 17 Suppl 10 2 5 1:CAS:528: DC%2BD38Xptlekt7k%3D 12386262
66. C Santori M Ceccanti D Diacinti, et al. 2008 Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol J Endocrinol Invest 31 4 321 326 1:CAS:528:DC%2BD1cXnsl2qtbY%3D 18475050
67. JL Gonzalez-Calvin JL Mundi FJ Casado-Caballero, et al. 2009 Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis J Clin Endocrinol Metab 94 12 4844 4850 1:CAS:528:DC%2BD1MXhsFyltLfJ 10.1210/jc.2009-0835 19897681
68. D Hegedus V Ferencz PL Lakatos, et al. 2002 Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease J Bone Miner Res 17 11 1961 1967 1:CAS:528:DC%2BD38Xoslems74%3D 10.1359/jbmr.2002.17. 11.1961 12412803
69. E Fabrega A Orive M Garcia-Unzueta, et al. 2006 Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation Clin Transplant 20 3 383 388 10.1111/j.1399-0012.2006.00497.x 16824158 (Pubitemid 43880576)
70. KB Tan J Harrop M Reddy, et al. 1997 Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells Gene 204 1-2 35 46 1:CAS:528:DyaK1cXivFWhsg%3D%3D 10.1016/S0378-1119(97)00509-X 9434163 (Pubitemid 28022168)